progestin primed ovarian stimulation protocol in patients with the polycystic ovarian syndrome in assisted reproductive technology cycles

The purpose of this study is to compare and compare pregnancy rates using progesterone prime protocol and antagonist protocol in patients with the polycystic ovarian syndrome who are the candidate for ART.

The clinical trial with the randomized control group

Randomized clinical trial without blindness,

Inclusion criteria: infertile PCOS patients which are the candidate for ART Exclusion criteria: women older than 40 years; history of endocrine disorder; intrauterine abnormality (uterine polyp & submucosal fibroma & intrauterine adhesions); severe endometriosis; and azoospermia of partner.

progesterone prime group: since the second day of the cycle all patients Will receive 150 unit of cinal f(cinagen-Iran) Subcutaneously and 20 mg dydrogesterone (Duphaston) orally. when dominant follicle reaches to 17 mm, final triggering will be done and 36 hours later. all embryo will be freez in cleavage stage and frozen embryo transfer will be done 2 months latter. Antagonist group: since the second day of the cycle all patients Will receive 150 unit of cinal f(cinagen-Iran) Subcutaneously When dominant follicle reached to 12-13 mm, cetrotide (Merck- Serono Germany).25 mg will be injected daily subcutaneously. when dominant follicle reaches to 17 mm, final triggering will be done and 36 hours later. all embryo will be freez in cleavage stage and frozen embryo transfer will be done 2 months later.

Clinical pregnancy rat

Update corrections and study results

Randomization will be done by sealed envelops.

Due to the privacy of patients

The study protocol, the statistical analysis map, the clinical study report will be available after the publishing of the article

After publishing the article

Researchers working in academic institutions

use in the retrospective study

Yazd research and clinical center for infertility

Request from the Research Deputy, submitted to the Research Council of the Center if the request accepts its referral to the security and after completion of the relevant forms, the request is referred to the research experts and then get the data. سایر توضیحات فا خالی

AbstractBackground: In vitro fertilization is an important therapy for women with the polycystic ovarian syndrome (PCOS). The use of new ways of improving clinical results is yet required. Objective: This study was aimed to investigate the efficacy of progesterone primed ovarian stimulation (PPOS) and compare with conventional antagonist protocol in PCOS.Materials and Methods:A total of 120 PCOS women who were candidates for assisted reproductive technology treatment were enrolled in this RCT and were placed into two groups, randomly (n = 60/each). The PPOS group received 20 mg/day Dydrogesterone orally since the second day of the cycle and the control group received antagonist protocol. The pregnancy outcomes including the chemical and clinical pregnancy, the miscarriage rate, and the percent of gestational sacs/transferred embryos were compared in two groups.Results:Number of MII oocyte, maturity rate, Number of 2 pronuclei (2PN) and serum estradiol levels on trigger day were statistically lower in PPOS group (p = 0.019, p =0.035, p = 0.032, p = 0.030), respectively. Serum LH level on trigger day in PPOSgroup was higher than antagonist group (p = 0.005). Although there wasn’t severe ovarian hyperstimulation syndrome in any participants, mild and moderate ovarian hyperstimulation syndrome was less in PPOS group (p = 0.001). Also, the chemical and clinical pregnancy rates were higher in the antagonist group, although it was not statistically significant (p = 0.136, p = 0.093 respectively).Conclusion: Our study demonstrates that PPOS does not improve the chemical and clinical pregnancy rate of infertile women with PCOS.